



2 8 MAR 2022

FDA ADVISORY No. 2022-0679

TO : ALL HEALTHCARE PROFESSIONALS AND THE

GENERAL PUBLIC

SUBJECT: Public Health Warning Against the Purchase and Use of

the following Verified Counterfeit Drug Products:

1. Phenylephrine HCl/ Chlorphenamine Maleate/ Paracetamol (Neozep®Forte) 10 mg / 2 mg / 500 mg Tablet


2. Dextromethorphan HBr/ Phenylpropanolamine HCl/ Paracetamol (Tuseran®Forte) 15 mg / 25 mg / 325 mg Capsule

3. Loperamide (Lomotil®) 2 mg Tablet

The Food and Drug Administration (FDA) advises the public against the purchase and use of the counterfeit version of the following products:



AUTHENTIC





COUNTERFEIT





Counterfeit – The tablet, logo knurling, security mark and print appearance are not comparable with the standard features of the registered product.

Figure 1. Comparison between the Authentic and Verified Counterfeit Phenylephrine HCl/ Chlorphenamine Maleate/ Paracetamol (Neozep®Forte) 10 mg / 2 mg / 500 mg Tablet (Lot No. 20110411)

AUTHENTIC





COUNTERFEIT





Counterfeit – The knurling, security mark and print appearance are not comparable with the standard features of the registered product.

Figure 2. Comparison between the Authentic and Verified Counterfeit Dextromethorphan HBr/ Phenylpropanolamine HCl/ Paracetamol (Tuseran®Forte) 15 mg / 25 mg / 325 mg Capsule (Lot No. U020368)

AUTHENTIC



og Tablet Asti-metitive 1221018F DR-XYZ7818	2mg Tabler Aris sorting 120008 DR-002764
Loperamide HCI	Loperamide HCI
Lomotil® 2mg Tablet Anti-monthly 1221018F DR-XY27814	Lontotil® Zmy Tablet Anti-motific 1221018F DR-XYZ7814
Loperamide HCI	Loperamide HCI
Lomotil® 2mg Tablet Antimotifity 122101BF DR-XY27914	Lomotil® 2mg Tablet Antiacotility 3223036F DR-XY27914
Loperamide HCI	Loperamide HCI
Lomotil®	Lomotil®
2mg Tablet Anti-metility 122101BF DR-XY27914	2mg Tablet Anti-metility 1221018F DR-XY27814
Loperamide HCI	Loperamide HCI
Lomotil® 2mg Tablet Anti-metility 1221018F DR-XY27914	Lomotil® 2mg Tablet Anti-motility
Loperamide HCI	Loperamide HCI
Lomotil® 2mg Tablet Astimotility	Lomotil®
	1221018F DR-XY27914
	Loperamide HCI
	Lomotil® 2mg Tablet Astimotility
	1221018F DR-XY27914
Property of the Party of the Pa	Loperamide HCI
Lomotil® 2mg Tablet Anti-motility 1221018F DR-XY27914	Zmg Tablet Anti-matrity 122101BF DR-XY27814
Loperamide HCI	Loperamide HCI
Lomotil®	Lomotil®
32101BF DR-XY2/914	122101E# DR-XYZ7814

COUNTERFEIT





Counterfeit – The batch no. was not manufactured by the Marketing Authorization Holder (MAH)

Figure 3. Comparison between the Authentic and Verified Counterfeit Loperamide (Lomotil®) 2 mg Tablet (Batch No. 19LMT06)

All healthcare professionals and the general public are hereby warned as to the availability of these counterfeit drug products in the market which pose potential danger or injury to consumers. Consumers are also reminded to purchase drug products only from FDA-licensed establishments.

Likewise, all establishments and outlets are hereby warned against selling and/or dispensing of the said counterfeit products with the abovementioned features. The importation, selling or offering for sale of such is in direct violation of Republic Act No. 9711 or the Food and Drug Administration Act of 2009, and Republic Act No. 8203 or the Special Law on Counterfeit Drugs. Anyone found selling the said counterfeit drug products will be penalized.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction

For more information and inquiries, please e-mail us at info@fda.gov.ph. To report continuous sale or distribution of unregistered health products, kindly e-mail us via ereport@fda.gov.ph, or through the online reporting facility, eReport, at www.fda.gov.ph/ereport. You may also call the Center for Drug Regulation and Research at telephone number (02) 8809-5596. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH and fill out all the required fields.

Dissemination of the information to all concerned is requested.

DR. OSCAR G. GUTIERREZ, JR. Officer-in-Charge Director General

DTN:

20220323075448